Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bruker and ImaBiotech Announces Collaboration

Published: Friday, June 21, 2013
Last Updated: Friday, June 21, 2013
Bookmark and Share
Bruker to distribute ImaBiotech's Quantinetix software for quantitative MALDI imaging.

Bruker and ImaBiotech have announced a collaboration for the distribution of ImaBiotech’s Quantinetix™ software. The Quantinetix software is the first independent multi-format software for MALDI instruments that quantifies and normalizes molecules.

Mass spectrometry MALDI imaging is a technique that allows for the direct detection of drugs and metabolites in tissue, and it is increasingly being adopted as a tool for pharmaceutical drug discovery and development.

But the absolute quantification of MALDI imaging data is challenging due to the complex matrix used (intact tissue) and the associated suppression of the ions that are essential to the measurement process.

ImaBiotech, a leading service provider for MALDI imaging, has incorporated its special quantification methods into the Quantinetix™ dedicated software package to address these challenges.

Quantinetix™ is user-friendly software that provides quantitation of target compounds following mass spectrometry imaging experiments.

It normalizes and quantifies molecules in several ways, providing images and quantitation of target compounds in over 25 organs when used for whole body distribution imaging, as well as for individual organs in targeted applications.

Dr. Sören-Oliver Deininger, Market Area Manager for MALDI Imaging at Bruker, noted, “ImaBiotech‘s Quantinetix™ software has helped transform MALDI imaging into a quantitative technique. With this collaboration, we are now able to directly provide our customers with the benefits of Quantinetix™, enabling them to achieve true quantitative results with their Bruker MALDI molecular imaging solution.”

Dr. Jonathan Stauber, CEO of ImaBiotech, added, “We are pleased to partner with Bruker. ImaBiotech’s know-how and efficiency in imaging complement Bruker’s renowned expertise in mass spectrometry. With this agreement, we are now able to offer this unparalleled technology to molecular researchers in the worldwide pharmaceutical and biomedical research industries.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bruker Opens New Preclinical Imaging Center of Excellence for the Americas
Massachusetts Center will provide advanced development, demonstration and customer support capabilities for Bracer’s unique multimodal preclinical imaging systems portfolio.
Thursday, January 30, 2014
Bruker Announces Acquisition of Prairie Technologies
Acquisition strengthens Bruker Nano Surfaces Division's position in life science markets.
Friday, September 13, 2013
Bruker to Acquire Carestream’s Preclinical In-vivo Imaging Business
Transaction positions in-vivo products for long-term growth.
Monday, September 24, 2012
Scientific News
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Potential Target for Revolutionary Antibiotics
An international team of including the Lomonosov Moscow State University researchers discovered which enzyme enables Escherichia coli bacterium (E. coli) to breathe.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!